Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICSUN: Mosunetuzumab + DA-EPOCH in Untreated c-Myc+ High-Grade B-Cell Lymphomas
NCT06249191Phase 2Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), sponsored by OHSU Knight Cancer Institute. Started Jun 2024; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT06249191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249191.